Navigation Links
Research provides new findings on drug delivery with nanoparticles
Date:3/1/2011

Researchers have over time been able to show that medicine designed at nanoscale offers unprecedented opportunities for targeted treatment of serious diseases such as cancer. However, now research also shows that the body's immune system plays a significant part in the drug delivery process.

"Researchers today are able encapsulate medicine in nanoparticles the size of viruses. The nanoparticles are effective for drug delivery the delivery of the medicine to the body because they can very precisely find diseased cells and carry the medicine to them. This means that you can suffice with less dosage and thereby fewer side effects," explains Professor Moein Moghimi from the Faculty of Pharmaceutical Sciences at the University of Copenhagen.

Professor Moghimi has along with colleagues at the University of Brighton and the Technical University of Denmark recently published a landmark paper in ACS Nano regarding the immune system's attack on nanoparticles.

The new research has shown that the coating of the nanoparticle surface has great influence on the activation of the immune system the particle's polymer coating can be designed in various ways, and the form can drastically change the body's immune response.

"Drug delivery with nanoparticles camouflaged as water soluble polymers has proven very effective. One way of delivering drugs safely to diseased sites in the body is to encapsulate them in small polymeric particles in similar size to viruses. However, when injected into the blood these particles are intercepted by the body's defence system. This can be overcome by camouflaging the surface of these nanocarriers with water soluble polymers. This makes the surface 'water-like' and less visible to the immune system," says Professor Moghimi.

Professor Moghimi works at the Department of Pharmaceutics and Analytical Chemistry where he heads the Centre for Pharmaceutical Nanotechnology and Nanotoxicology, which is supported by the Danish Agency for Science, Technology and Innovation. This work was done as part of ongoing research at the Centre.

Professor Moghimi's main focus is nanotoxicology and the possible consequences of drug delivery with nanoparticles.

"Our newest research indicates that we should be very cautious when designing the surface of the nanoparticles. Remarkably, changing the conformation of the coating polymers on nanoparticle surface from a 'mushroom-type' to a 'brush-type' appearance can switch complement activation from one pathway to another," explains Professor Moghimi.

The research demonstrates difficulty in design and surface engineering of polymeric nanoparticles such that it is hydrophilic enough to be compatible with biological fluids and yet prevent complement activation.

This is also very important from clinical perspectives since complement activation may induce adverse reactions in some patients.

The importance of this work was also highlighted in an all exclusive "News and Views" by the prestigious Nature Nanotechnology.


'/>"/>

Contact: Moein Moghimi
momo@farma.ku.dk
455-121-7975
University of Copenhagen
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel of ... of proceeds to two local organizations: North Chicago Animal Control and Friends and Our ... a team of authorized and trained volunteers who support rescued animals held in the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies and ... scam operations to a halt. According to Texas Premier Locksmith, these fraudulent locksmith ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... The ... the holidays and winter seasons. One major study analyzing heart attacks among 138,602 ... to August of a given year. We would all agree of course–no time of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen ... Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years ... three acupuncturists to help patients realize their family building goals. Acupuncture helps ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- KEY FINDINGS Patient warming and ... loss of blood during surgeries, lowering the risks ... after surgeries, and decreasing risks of SSIs. The ... warming system, surface warming systems, and intravascular warming ... at hospitals thus, lowering the healthcare costs by ...
(Date:12/7/2016)... 7, 2016 Research and Markets has announced ... User - Global Forecast to 2021" report to their offering. ... , , ... by 2021, growing at a CAGR of 7.3% during the forecast period ... prevalence of cancer and rapidly increasing geriatric population across the globe are ...
(Date:12/7/2016)... Dec. 7, 2016 DelveInsight,s, "Janus ... provides in depth insights on the pipeline ... Janus Kinase 3 (JAK3) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Medicine Technology: